🇺🇸 FDA
Patent

US 11197869

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

granted A61KA61K31/5685A61K45/06

Quick answer

US patent 11197869 (Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)) held by Windtree Therapeutics, Inc. expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Windtree Therapeutics, Inc.
Grant date
Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/5685, A61K45/06, A61K9/009, A61P